Coherus Oncology, Inc. (CHRS)

Every figure this model derived for CHRS, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-12-31
cash 105,306,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 133,788,000 AssetsCurrent 2026-06-30
current liabilities 75,510,000 LiabilitiesCurrent 2026-06-30
equity 60,838,000 StockholdersEquity 2026-06-30
interest expense 9,083,000 InterestExpense 2026-06-30
ocf -186,031,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 50,936,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 11,141,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CHRS on one particular measure came for.

RatioValue
cash operating margin-282.61
current ratio1.77
current ratio reported1.77
deferred revenue growth-98.65
dilution pct2.26
ev owner earnings-0.49
ev sales1.91
fcf margin-365.22
interest cover-17.47
operating margin-311.56
owner earnings margin-387.1
revenue growth61.0
revenue growth per share57.43
rule of 40-250.56
sbc pct revenue21.87

What to be careful about

What this model itself distrusts about CHRS's figures. Written by the derivation as it ran, not added afterwards.